Paracoccidioidomycosis: Eco-epidemiology, taxonomy and clinical and therapeutic issues

Future Microbiology

Volumn 8, Issue 9, 2013, Pages 1177-1191

  Bocca, Anamelia Lorenzetti ^a   Amaral, André Corrêa ^b   Teixeira, Marcus Melo ^a   Sato, Paula ^c   Shikanai Yasuda, Maria Aparecida ^c   Soares Felipe, Maria Sueli ^a,d  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

Author keywords

DNA vaccine; epidemiology; nanostructures; paracoccidioidomycosis

Indexed keywords

AMPHOTERICIN B; DNA VACCINE; PYRROLE DERIVATIVE; SULFONE DERIVATIVE;

ADRENAL GLAND; DISEASE COURSE; ECOLOGY; HOST; HUMAN; IMMUNE RESPONSE; LUNG DISEASE; LYMPH NODE; LYMPHADENOPATHY; MUCOSA; NONHUMAN; PARACOCCIDIOIDES; PARACOCCIDIOIDES BRASILIENSIS; PARACOCCIDIOIDES LUTZII; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SOUTH AMERICAN BLASTOMYCOSIS; SURVIVAL TIME; TAXONOMY; TREATMENT OUTCOME;

ADRENAL GLANDS; ANTIFUNGAL AGENTS; CHRONIC DISEASE; DERMATOMYCOSES; HUMANS; LUNG DISEASES, FUNGAL; LYMPH NODES; LYMPHATIC DISEASES; MALE; MUCOUS MEMBRANE; PARACOCCIDIOIDES; PARACOCCIDIOIDOMYCOSIS; VACCINES, DNA;

EID: 84884166899     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.68     Document Type: Review

References (109)

1. Coutinho ZF, Silva D, Lazera M et al. Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad. Saude Publica 18, 1441-1454 (2002).
2. Franco M, Bagagli E, Scapolio S, Lacaz CS. A critical analysis of Paracoccidioides brasiliensis from soil. Med. Mycol. 38, 185-191 (2000).
3. Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, Colombo AL, Moretti ML. Guidelines in paracoccidioidomycosis. Rev. Soc. Bras. Med. Trop. 39, 297-310 (2006).
4. Brummer E, Castaneda E, Restrepo A. Paracoccidiodomycosis: an update. Clin. Microbiol. Res. 6, 89-117 (1993).
5. Buitrago MJ, Bernal-Martínez L, Castelli MV, Rodriguez-Tudela JL, Cuenca-Estrella M. Histoplasmosis and paracoccidioidomycosis in a non-endemic area: a review of cases and diagnosis. J. Travel Med. 18, 26-33 (2011).
6. Shankar J, Restrepo A, Clemons KV, Stevens DA. Hormones and the resistance of women to paracoccidioidomycosis. Clin. Microbiol. Rev. 24, 296-313 (2011).
7. dos Santos WA, da Silva BM, Passos ED, Zandonade E, Falqueto A. [Association between smoking and paracoccidioidomycosis: a case control study in the state of Espirito Santo, Brazil]. Cad. Saude Publica 19, 245-253 (2003).
8. Barrozo LV, Benard G, Silva ME, Bagagli E, Marques SA, Mendes RP. First description of a cluster of acute/subacute paracoccidioidomycosis cases and its association with a climatic anomaly. PLoS Negl. Trop. Dis. 4, e643 (2010).
9. Barrozo LV, Mendes RP, Marques SA, Benard G, Silva ME, Bagagli E. Climate and acute/subacute paracoccidioidomycosis in a hyperendemic area in Brazil. Int. J. Epidemiol. 38, 1642-1649 (2009).
10. Restrepo A, McEwen JG, Castaneda E. The habitat of Paracoccidioides brasiliensis: how far from solving the riddle? Med. Mycol. 39, 233-241 (2001).
11. Silva-Vergara ML, Martinez R, Chadu A, Madeira M, Freitas-Silva G, Leite Maffei CM. Isolation of a Paracoccidioides brasiliensis strain from the soil of a coffee plantation in Ibiá, State of Minas Gerais, Brazil. Med. Mycol. 36(1), 37-42 (1998).
12. Theodoro RC, Candeias JMG, Araújo JP Jr et al. Molecular detection of Paracoccidioides brasiliensis in soil. Med. Mycol. 43, 725-729 (2005).
13. Terçarioli GR, Bagagli E, Reis GM et al. Ecological study of Paracoccidioides brasiliensis in soil: growth ability, conidia production and molecular detection. BMC Microbiol. 7, 92 (2007).
14. San-Blas G, Nino-Vega G, Iturriaga T. Paracoccidioides brasiliensis and paracoccidioidomycosis: molecular approaches to morphogenesis, diagnosis, epidemiology, taxonomy and genetics. Med. Mycol. 40, 225-242 (2002).
15. Teixeira MD, Theodoro RC, Derengowsky LD, Nicole AM, Bagagli E, Felipe MS. Molecular and morphological data supports the existence of a sexual cycle in species of the genus Paracoccidioides. Eukaryot. Cell 12, 380-389 (2013).
16. Bagagli E, Franco M, Bosco Sde M, Hebeler-Barbosa F, Trinca LA, Montenegro MR. High frequency of Paracoccidioides brasiliensis infection in armadillos (Dasypus novemcinctus): an ecological study. Med. Mycol. 41, 217-223 (2003).
17. Corredor GG, Castaño JH, Peralta LA et al. Isolation of Paracoccidioides brasiliensis from the nine-banded armadillo Dasypusnovemcinctus, in an endemic area for paracoccidioidomycosis in Colombia. Rev. Iberoam. Micol. 16, 216-220 (1999).
18. Bagagli E, Bosco SM, Theodoro RC, Franco M. Phylogenetic and evolutionary aspects of Paracoccidioides brasiliensis reveal a long coexistence with animal hosts that explain several biological features of the pathogen. Infect. Genet. Evol. 6, 344-351 (2006).
19. Farias MR, Condas LA, Ribeiro MG et al. Paracoccidioidomycosis in a dog: case report of generalized lymphadenomegaly. Mycopathologia 172, 147-152 (2011).
20. Trejo-Chavez A, Ramírez-Romero R, Ancer-Rodriguez J, Nevarez-Garza AM, Rodriguez-Tovar LE. Disseminated paracoccidioidomycosis in a Southern two-toed sloth (Choloepusdidactylus). J. Comp. Pathol. 144, 231-234 (2011).
21. Gezuele E. Aislamiento de Paracoccidioides sp. de heces de un pingüino de la Antártida. In: Proceedings IV International Symposium on Paracoccidioidomycosis. Caracas, Venezuela, 10-14 April 1989 (Abstract B2).
22. Grose E, Tamsitt JR. Paracoccidioides brasiliensis recovered from the intestinal tract of three bats (Artibeuslituratus) in Colombia, SA. Sabouraudia 4, 124-125 (1965).
23. Conti-Diaz IA, Alvarez BJ, Gezuele E, González Marini H, Duarte J, Falcón J. [Intradermal reaction survey with paracoccidioidin and histoplasmin in horses]. Rev. Inst. Med. Trop. Sao Paulo. 14(6), 372-376 (1972).
24. Gutierrez AH, Ceballos GC, Ferrer HI, Rangel O. [Survey of tuberculosis, histoplasmosis and paracoccidioidomycosis in dairy cattle in the Aburra valley.] Antioq. Med. 24, 339-358 (1974).
25. Fontana FF, dos Santos CT, Esteves FM et al. Seroepidemiological survey of paracoccidioidomycosis infection among urban and rural dogs from Uberaba, Minas Gerais, Brazil. Mycopathologia 169, 159-165 (2010).
26. Johnson WD, Lang CM. Paracoccidioidomycosis (South American blastomycosis) in a squirrel monkey (Saimiri sciureus). Vet. Pathol. 14(4), 368-371 (1977).
27. Corte AC, Svoboda WK, Navarro IT et al. Paracoccidioidomycosis in wild monkeys from Paraná State, Brazil. Mycopathologia 164, 225-228 (2007).
28. Richini-Pereira VB, Bosco S de M, Griese J et al. Molecular detection of Paracoccidioides brasiliensis in road-killed wild animals. Med. Mycol. 18, 1-6 (2007).
29. Arantes TD, Theodoro RC, Da Graça Macoris SA, Bagagli E. Detection of Paracoccidioides spp. in environmental aerosol samples. Med. Mycol. 51, 83-92 (2013).
30. Teixeira MM, Theodoro RC, de Carvalho MJ et al. Phylogenetic analysis reveals a high level of speciation in the Paracoccidioides genus. Mol. Phylogenet. Evol. 52, 273-283 (2009).
31. Untereiner WA, Scott JA, Naveau FA, Sigler L, Bachewich J, Angus A. The Ajellomycetaceae, a new family of vertebrate-associated Onygenales. Mycologia 96, 812-821 (2004).
32. Almeida FP. Estudos comparativos do granuloma coccidióidico nos Estados Unidos e no Brasil. Novo gěnero para o parasita brasileiro. Fac. Med. Univ. São Paulo 5, 125-141 (1930).
33. Teixeira MM, Theodoro RC, Oliveira FF et al. Paracoccidioides lutzii sp. nov.: biological and clinical implications. Med. Mycol. doi:10.3109/13693786. 2013.794311 (2013) (Epub ahead of print).
34. Molinari-Madlum EE, Felipe MS, Soares CM. Virulence of Paracoccidioides brasiliensis isolates can be correlated to groups defined by random amplified polymorphic DNA analysis. Med. Mycol. 37, 269-276 (1999).
35. Marques-da-Silva SH, Rodrigues AM, de Hoog GS, Silveira-Gomes F, Camargo ZP. Occurrence of Paracoccidioides lutzii in the Amazon region: description of two cases. Am. J. Trop. Med. Hyg. 87, 710-714 (2012).
36. Theodoro RC, Teixeira MM, Felipe MS et al. Genus Paracoccidioides: species recognition and biogeographic aspects. PLoS ONE 7, e37694 (2012).
37. Hahn RC, Macedo AM, Fontes CJ, Batista RD, Santos NL, Hamdan JS. Randomly amplified polymorphic DNA as a valuable tool for epidemiological studies of Paracoccidioides brasiliensis. J. Clin. Microbiol. 41, 2849-2854 (2003).
38. Marini MM, Zanforlin T, Santos PC et al. Identification and characterization of Tc1/mariner-like DNA transposons in genomes of the pathogenic fungi of the Paracoccidioides species complex. BMC Genomics 11, 130 (2010).
39. Desjardins CA, Champion MD, Holder JW et al. Comparative genomic analysis of human fungal pathogens causing paracoccidioidomycosis. PLoS Genet. 7, e1002345 (2011).
40. Matute DR, McEwen JG, Puccia R et al. Cryptic speciation and recombination in the fungus Paracoccidioides brasiliensis as revealed by gene genealogies. Mol. Biol. Evol. 23, 65-73 (2006).
41. Salgado-Salazar C, Jones LR, Restrepo A, McEwen JG. The human fungal pathogen Paracoccidioides brasiliensis (Onygenales: Ajellomycetaceae) is a complex of two species: phylogenetic evidence from five mitochondrial markers. Cladistics 26, 613-624 (2010).
42. Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA. Immunology of paracoccidioidomycosis. An. Bras. Dermatol. 86, 516-524 (2011).
43. Arruda C, Valente-Ferreira RC, Pina A et al. Dual role of interleukin-4 (IL-4) in pulmonary paracoccidioidomycosis: endogenous IL-4 can induce protection or exacerbation of disease depending on the host genetic pattern. Infect. Immun. 72, 3932-3940 (2004).
44. Da Silva FC, Svidzinski TIE, Patussi EV, Cardoso CP, De Oliveira Dalalio MM, Hernandes L. Morphologic organization of pulmonary granulomas in mice infected with Paracoccidioides brasiliensis. Am. J. Trop. Med. Hyg. 80, 798-804 (2009).
45. Felonato M, Pina A, Bernardino S, Loures FV, de Araujo EF, Calich VL. CD28 exerts protective and detrimental effects in a pulmonary model of paracoccidioidomycosis. Infect. Immun. 78, 4922-4935 (2010).
46. Loures FV, Pina A, Felonato M, Calich VL. TLR2 is a negative regulator of Th17 cells and tissue pathology in a pulmonary model of fungal infection. J. Immunol. 183(2), 1279-1290 (2009).
47. Benard G, Romano CC, Cacere CR, Juvenale M, Mendes-Giannini MJS, Duarte AJS. Imbalance of IL-2, IFN-g and IL-10 secretion in the immunosuppression associated with human paracoccidioidomycosis. Cytokine 13, 248-252 (2001).
48. Oliveira SJ, Mamoni RL, Musatti CC, Papaiordanou PM, Blotta MH. Cytokines and lymphocyte proliferation in juvenile and adult forms of paracoccidioidomycosis: comparison with infected and non-infected controls. Microbes Infect. 4(2), 139-144 (2002).
49. Mamoni RL, Blotta MH. Flow-cytometric analysis of cytokine production in human paracoccidioidomycosis. Cytokine 35, 207-216 (2006).
50. Pagliari C, Fernandes ER, Stegun FW, da Silva WL, Seixas Duarte MI, Sotto MN. Paracoccidioidomycosis: cells expressing IL17 and Foxp3 in cutaneous and mucosal lesions. Microb. Pathog. 50(5), 263-267 (2011).
51. Sadahiro A, Roque ACM, Shikanai-Yasuda MA. Generic human leukocyte antigen class II (DRB1 and DQB1) alleles in patients with paracoccidioidomycosis. Med. Mycol. 45, 35-40 (2007).
52. Bozzi A, Reis BS, Pereira PP, Pedroso EP, Goes AM. Interferon-gamma and interleukin-4 single nucleotide gene polymorphism in paracoccidoidomycosis. Cytokine 48, 212-217 (2009).
53. Franco M, Montenegro MR, Mendes RP, Marques SA, Dillon ML, Mota NGS. Paracoccidioidomycosis: a recently proposed classification of its clinical forms. Rev. Soc. Bras. Med. Trop. 20, 129-132 (1987).
54. Severo LC, Geyer GR, Londero AT, Porto NS, Rizzon CF. The primary pulmonary lymph node complex in paracoccidioidomycosis. Mycopathologia 67, 115-118 (1979).
55. Martinez R. Digestive disorders. In Paracoccidioidomicose: Blastomicose Sul-Americana. Del Negro G, Lacaz CS, Fiorillo A (Eds). Sarvier-EDUSP, Brazil, 61-170 (1992).
56. Shikanai-Yasuda MA, Higaki Y, Uip DE, Mori NS, Del Negro G, Melo NT, Hutzler RU, Amato Neto V. Comprometimento da medula óssea e eosinofilia na paracoccidioidomicose. Rev. Inst. Med. Trop. Sao Paulo 34(2), 85-90 (1992).
57. Morejón KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am. J. Trop. Med. Hyg. 80, 359-366 (2009).
58. Shikanai-Yasuda MA, Telles Filho FQ, Mendes RP et al. Consenso em paracoccidioidomicose. Rev. Soc. Bras. Med. Trop. 39(3), 297-310, (2006).
59. Del Negro G, Melo EH, Rodbard D, Melo MR, Layton J, Wachslicht-Rodbard H. Limited adrenal reserve in paracoccidioidomycosis: cortisol and aldosterone responses to 1-24 ACTH. Clin. Endocrinol. (Oxf.) 13, 553-559 (1980).
60. Reis F, Collier PP, Souza TF et al. Neuroparacoccidioidomycosis (NPCM): magnetic resonance imaging (MRI) findings. Mycopathologia 175, 181-186 (2013).
61. Paniago AMM, Aguiar JIA, Aguiar ES et al. [Paracoccidioidomycosis: a clinical and epidemiological study of 422 cases observed in Mato Grosso]. Rev. Soc. Bras. Med. Trop. 36, 455-459 (2003).
62. Ratto OR. Lesões pulmonares. Aspectos clínicos e funcionais. In: Paracoccidioidomicose: Blastomicose Sul-Americana. Del Negro G, Lacaz CS, Fiorillo A (Eds). Sarvier-EDUSP, Brazil, 61-170 (1982).
63. Wanke B, Aidě MA. Chapter 6-paracoccidioidomycosis. J. Bras. Pneumol. 35(12), 1245-1249 (2009).
64. Shikanai-Yasuda MA, Cotrim Segurado AA, Pinto WP et al. Immunodeficiency secondary to juvenile paracoccidioidomycosis: secondary infections. Mycopathologia 129, 23-28 (1992).
65. Shikanai-Yasuda MA. Pharmacological management of paracoccidioidomycosis. Expert Opin. Pharmacother. 6, 385-397 (2005).
66. Shikanai-Yasuda MA, Conceição YM, Kono A, Rivitti E, Campos AF, Campos SV. Neoplasia and paracoccidioidomycosis. Mycopathologia 165(4-5), 303-312 (2008).
67. Sugar AM, Restrepo A, Stevens DA. Paracoccidioidomycosisin the immunosupressed host: report of a case and review of the literature. Am. Rev. Resp. Dis. 129, 340-342 (1984).
68. Shikanai-Yasuda MA, Duarte MI, Nunes DF et al. Paracoccidioidomycosis in a renal transplant recipient. J. Med. Vet. Mycol. 33, 411-414 (1995).
69. Zavascki AP, Bienardt JC, Severo LC. Paracoccidioidomycosis in organ transplant recipient: case report. Rev. Inst. Med. Trop. Sao Paulo 46, 279-281 (2004).
70. Bertolini TA, Perenha-Viana MCZ, Patussi EV, Cardoso RF, Svidzinski TI. Western blotting is an efficient tool for differential diagnosis of paracoccidioidomycosis and pulmonary tuberculosis. Clin. Vaccine Immunol. 19, 1887-1888 (2012).
71. Perenha-Viana MCZ, Gonzales IAA, Brockelt SR et al. Serological diagnosis of paracoccidioidomycosis through a western blot technique. Clin. Vaccine Immunol. 19, 616-619 (2012).
72. Matute DR, Quesada-Ocampo LM, Rauscher JT, McEwen JG. Evidence for positive selection in putative virulence factors within the Paracoccidioides brasiliensis species complex. PLoS Negl. Trop. Dis. 2, e29 (2008).
73. Batista J Jr, de Camargo ZP, Fernandes GF, Vicentini AP, Fontes CJ, Hahn RC. Is the geographical origin of a Paracoccidioides brasiliensis isolate important for antigen production for regional diagnosis of paracoccidioidomycosis? Mycoses 53, 176-180 (2010).
74. Do Valle AC, Costa RL, Fialho Monteiro PC, Von Helder J, Muniz MM, Zancopé-Oliveira RM. Interpretation and clinical correlation of serological tests in paracoccidioidomycosis. Med. Mycol. 39, 373-377 (2001).
75. Rigobello FF, Marques AS, Lopes JD, Nakanishi FA, Itano EN. Patients with chronic-form paracoccidioidomycosis present high serum levels of IgE anti-Paracoccidioides brasiliensis gp70. Mycopathologia 175, 307-313 (2013).
76. Marques da Silva SH, Colombo AL, Blotta MH, Lopes JD, Queiroz-Telles F, Pires de Camargo Z. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and broncho alveolar lavage fluid of patients with paracoccidioidomycosis. J. Clin. Microbiol. 41, 3675-3680 (2003).
77. Shikanai-Yasuda MA, Benard G, HigakiY et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med. Mycol. 40, 411-417 (2002).
78. Queiroz-Telles F, Escuissato DL. Pulmonary paracoccidioidomycosis. Semin. Respir. Crit. Care Med. 32, 764-774 (2011).
79. Restrepo A, Gómes BL, Tobón A. Paracoccidioidomycosis: Latin America's own fungal disorder. Curr. Fungal Infect Rep. 6, 303-311 (2012).
80. Marques SA. Paracoccidioidomycosis. Clin. Dermatol. 30, 610-615 (2012).
81. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai-Yasuda MA. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin. Infect. Dis. 45, 1462-1469 (2007).
82. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37, 728-732 (2003).
83. Benard G, Campos A, Netto LC et al. Treatment of severe forms of paracoccidioidomycosis: is there a role for corticosteroids Med. Mycol. 50, 641-648 (2012).
84. Naranjo TW, Lopera DE, Diaz-Granados LR, Duque JJ, Restrepo AM, Cano LE. Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice. Pulm. Pharmacol. Ther. 24, 81-91 (2001).
85. Ribeiro AM, Bocca AL, Amaral ACF et al. DNAhsp65 vaccination induces protection in mice against Paracoccidioides brasiliensis infection. Vaccine 27, 606-613 (2009).
86. Ribeiro AM, Souza ACO, Amaral AC et al. Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection. J. Biomed. Nanotechnol. 9, 221-230 (2013).
87. Pinto AR, Puccia R, Diniz SN, Franco MF, Travassos LR. DNA-based vaccination against murine paracoccidioidomycosis using the gp43 gene from Paracoccidioides brasiliensis. Vaccine 18, 3050-3058 (2000).
88. Rittner GM, Muñoz JE, Marques AF, Nosanchuk JD, Taborda CP, Travassos LR. Therapeutic DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis. PLoS Negl. Trop. Dis. 6, e1519 (2012).
89. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5, 13-28 (2007).
90. Ting PC, Walker SS. New agents to treat life-threatening fungal infections. Curr. Top. Med. Chem. 8, 592-602 (2008).
91. Schmid E, Smith D. Is declining innovation in the pharmaceutical industry a myth? Drug Discov. Today 10, 1011-1012 (2005).
92. Abadio AKR, Kioshima ES, Teixeira MM, Martins NF, Maigret B, Felipe MSS. Comparative genomics allowed the identification of drug targets against human fungal pathogens. BMC Genomics 12, 75-85 (2011).
93. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 26, 7260-7275 (2005).
94. Nahar M, Dutta T, Murugesan S et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther. Drug Carrier Syst. 23, 259-318 (2006).
95. Okassa LN, Marchais H, Douziech-Eyrolles L et al. Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles. Eur. J. Pharm. Biopharm. 67(1), 31-38 (2007).
96. Kleinberg M. What is the current and future status of conventional amphotericin B? Int. J. Antimicrob. Agents 27(Suppl. 1), 12-16 (2006).
97. Baginski M, Sternal K, Czub J, Borowski E. Molecular modelling of membrane activity of amphotericin B, a polyene macrolide antifungal antibiotic. Acta Biochim. Pol. 52, 655-658 (2005).
98. Amaral AC, Bocca AL, Ribeiro AM et al. Amphotericin B in poly(lactic-co-glycolic acid) PLGA and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J. Antimicrob. Chemother. 63, 526-533 (2009).
99. Xu N, Gu J, Zhu Y, Wen H, Ren Q, Chen J. Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice. Int. J. Nanomed. 6, 905-913 (2011).
100. Jain S, Valvi PU, Swarnakar NK, Thanki K. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol. Pharm. 9, 2542-2553 (2012).
101. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis. 40 (Suppl. 6), S414-S421 (2006).
102. Amaral AC, Marques AF, Muñoz JE et al. Poly (lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis. Br. J. Pharmacol. 159, 1126-1132 (2010).
103. Van de Ven H, Paulussen C, Feijens PB et al. PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to fungizone and ambisome. J. Control Release 161, 795-803 (2012).
104. Marques AF, da Silva MB, Juliano MA, Travassos LR, Taborda CP. Peptide immunization as an adjuvant to chemotherapy in mice challenged intratracheally with virulent yeast cells of Paracoccidioides brasiliensis. Antimicrob. Agents Chemother. 50, 2814-2819 (2008).
105. Travassos LR, Rodrigues EG, Iwaki LK, Taborda CP. Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy. Mycopathologia 165, 341-352 (2008).
106. de Amorin J, Magalhães A, Muñoz JE et al. DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis induces long-term protection in presence of regulatory T cells. Microbes Infect. 15(3), 181-191 (2013).
107. Clawson C, Huang CT, Futalan D et al. Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine 5, 651-661 (2010).
108. Cunha-Azevedo EP, Silva JR, Martins OP et al. In vitro antifungal activity and toxicity of itraconazole in DMSA-PLGA nanoparticles. J. Nanosci. Nanotechnol. 11(3), 2308-2314 (2011).
109. Essa S, Louhichi F, Raymond M, Hildgen P. Improved antifungal activity of itraconazole-loaded PEG/PLA nanoparticles. J. Microencapsul. 30, 205-217 (2013).